ELV Elevance Health
Blue franchise in a cyclical cost trough; price only works if margins recover to 5.5%.
The story
Elevance is the largest Blue Cross Blue Shield licensee, a scaled managed-care franchise spanning commercial, Medicaid, Medicare Advantage, and a growing Carelon services arm (pharmacy, behavioral, care delivery). Its moat is the exclusive Blue brand in 14 states, local provider network discounts, and scale in claims data. Today it is a mature business going through a cyclical margin trough, hurt by Medicaid redetermination acuity shifts, elevated Medicare Advantage utilization, and ACA risk-pool deterioration. Repricing, benefit cuts, and Carelon mix should restore margins toward the industry's normal mid-single digits, though probably not to past peaks.
Year-1 growth is modest because the company is pruning unprofitable membership and repricing. Over the horizon, growth runs at medical cost trend plus Carelon expansion before settling at 3% terminal, below the 4.95% risk-free rate. Margin recovers from 3.6% TTM to 5.5% over four years, which is below the 2022 peak of 5.4%-plus and in line with long-run managed-care economics. Sales-to-capital of 3.0 reflects a capital-light insurance float model, slightly above the trailing 2.65 as acquisition spending slows. Beta of 0.9 matches the industry anchor, and failure risk is minimal for a firm this size.
Value drivers
| Revenue growth (Y1) | 4.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 8y |
| Target operating margin | 5.5% |
| Years to target margin | 4 |
| Sales-to-capital | 3.00 |
| Beta | 0.90 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.3% |
| Terminal WACC | 8.6% |
Valuation bridge
| PV of explicit FCFF | 42.10B |
| PV of terminal value | 77.43B |
| Equity value | 95.86B |
| ÷ shares → per share | $442.04 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 209.16B | 4.0% | 4.1% | 7.23B | 2.68B | 4.55B | 4.20B |
| 2 | 217.23B | 3.9% | 4.6% | 8.37B | 2.69B | 5.68B | 4.84B |
| 3 | 225.29B | 3.7% | 5.0% | 9.57B | 2.69B | 6.88B | 5.41B |
| 4 | 233.34B | 3.6% | 5.5% | 10.83B | 2.68B | 8.15B | 5.92B |
| 5 | 241.34B | 3.4% | 5.5% | 11.20B | 2.67B | 8.53B | 5.73B |
| 6 | 249.27B | 3.3% | 5.5% | 11.57B | 2.64B | 8.92B | 5.53B |
| 7 | 257.10B | 3.1% | 5.5% | 11.93B | 2.61B | 9.32B | 5.33B |
| 8 | 264.82B | 3.0% | 5.5% | 12.29B | 2.57B | 9.72B | 5.13B |
Key risks
- Medical cost trend stays elevated longer than repricing can offset, keeping margins near 4%
- Medicare Advantage rate notices, risk-adjustment (V28) changes, or star-rating losses compress government segment profits
- Medicaid policy shifts and federal funding cuts reduce enrollment and squeeze state rate adequacy
Catalysts
- 2027 commercial and MA bid repricing showing visible MLR improvement
- Carelon Rx and CarelonServices growth lifting the share of higher-margin fee revenue